The Sybil prophecy: Searching for predictors of response to bevacizumab in glioblastoma

被引：0
|
作者：
Offi, Martina [1 ,2 ]
Gabriele, Lucia [1 ,3 ]
Romagnoli, Giulia [3 ]
Lauretti, Liverana [2 ]
Pallini, Roberto [1 ,2 ]
D'Alessandris, Quintino Giorgio [1 ,2 ]
机构：
[1] Catholic Univ, Sch Med, Dept Neurosci, Largo A Gemelli 8, I-00168 Rome, Italy
[2] Fdn Policlin Gemelli IRCCS, Dept Neurosurg, Largo A Gemelli 8, I-00168 Rome, Italy
[3] Ist Super Sanita, Dept Oncol & Mol Med, Rome, Italy
来源：
NEURO-ONCOLOGY | 2024年 / 26卷 / 08期
关键词：
D O I：
10.1093/neuonc/noae088
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1538 / 1539
页数：2
相关论文
共 50 条
  • [1] Sybil Erithea. Papacy and Prophecy in the Thirteenth Century
    Carozzi, Claude
    REVUE BELGE DE PHILOLOGIE ET D HISTOIRE, 2008, 86 (3-4): : 922 - 923
  • [2] Profiling response to carmustine/bevacizumab in recurrent glioblastoma.
    Rojas, Leonardo
    Cardona, Andres F.
    Wills, Beatriz
    Arrieta, Oscar
    Vargas, Carlos A.
    Carranza, Hernan
    Otero, Jorge M.
    Useche, Nicolas
    Bermudez, Sonia
    Jimenez, Enrique
    Hakim, Fernando
    Balana, Carmen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] Predicting glioblastoma response to bevacizumab through marker profiling?
    Kessler, Tobias
    NEURO-ONCOLOGY, 2016, 18 (02) : 149 - 150
  • [4] PRIMARY SPINAL CORD GLIOBLASTOMA: RESPONSE TO THERAPY WITH BEVACIZUMAB
    Walbert, Tobias
    Puduvalli, Vinay
    NEURO-ONCOLOGY, 2010, 12 : 44 - 44
  • [5] Bevacizumab for glioblastoma
    Narita, Yoshitaka
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 1759 - 1765
  • [6] Genomic Predictors of Imaging Response and Survival in Glioblastoma
    Soike, M.
    McTyre, E.
    Holmes, J. A.
    Paulsson, A. K.
    Miller, L.
    Lesser, G. J.
    Strowd, R. E.
    Johnson, A.
    Lo, H. W.
    Laxton, A. W.
    Tatter, S. B.
    Debinski, W.
    Chan, M. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E121 - E122
  • [7] Genetic analyses for predictors of radiation response in glioblastoma
    Shih, HA
    Betensky, RA
    Dorfman, MV
    Louis, DN
    Loeffler, JS
    Batchelor, TT
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (03): : 704 - 710
  • [8] Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab
    Prados, Michael
    Cloughesy, Timothy
    Samant, Meghna
    Fang, Liang
    Wen, Patrick Y.
    Mikkelsen, Tom
    Schiff, David
    Abrey, Lauren E.
    Yung, W. K. Alfred
    Paleologos, Nina
    Nicholas, Martin K.
    Jensen, Randy
    Vredenburgh, James
    Das, Asha
    Friedman, Henry S.
    NEURO-ONCOLOGY, 2011, 13 (01) : 143 - 151
  • [9] A prognostic model for clinical response to bevacizumab in recurrent glioblastoma multiforme
    Urup, Thomas
    Michaelsen, Signe Regner
    Holst, Camilla Bjornbak
    Toft, Anders
    Christensen, Ib Jarle
    Grunnet, Kirsten
    Kosteljanetz, Michael
    Broholm, Helle
    Lassen, Ulrik
    Poulsen, Hans Skovgaard
    CANCER RESEARCH, 2015, 75
  • [10] Hypertension and proteinuria as clinical biomarkers of response to bevacizumab in glioblastoma patients
    Bruno Carvalho
    Rafaela Gonçalves Lopes
    Paulo Linhares
    Andreia Costa
    Cláudia Caeiro
    Ana Catarina Fernandes
    Nuno Tavares
    Lígia Osório
    Rui Vaz
    Journal of Neuro-Oncology, 2020, 147 : 109 - 116
12345